In a crossover trial of 58 people with severe COPD and persistent dyspnoea (37 completed), neither transdermal fentanyl nor oral morphine improved mean daily dyspnoea score versus placebo; no differences in secondary outcomes or side-effects except possibly vomiting.
RCTn = 58
van Dijk et al. Fentanyl or morphine for persistent dyspnoea in COPD: a multicentre randomised crossover trial